Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Burdock Root

Finding The Right Connection After Spinal Cord Injury
In a major step in spinal cord injury research, scientists at the University of California, San Diego School of Medicine have demonstrated that regenerating axons can be guided to their correct targets and re-form connections after spinal cord injury. Their findings were published in the advance online edition of the journal Nature Neuroscience on August 2.
generic viagra online
RCN Calls For EU Agreement On Sharps Injuries To Be Implemented Quickly
The Royal College of Nursing welcomed the signing of a joint agreement by European Federation of Public Service Unions (EPSU) and the European Hospital and Healthcare Employers Association (HOSPEEM). This is an EU-wide agreement which the RCN has played a key role in bringing about to prevent one million medical sharps injuries per year. Dr Peter Carter, Chief Executive of the Royal College of Nursing (RCN), said:
News of the day
New Study Highlights Threat Of Resistance To Artemisinin-Based Anti-Malarial Drugs
Malaria parasites in western Cambodia have become resistant to artemisinin-based therapies, the first-line treatment for malaria, according to a study published in the New England Journal of Medicine. Resistance to the drugs makes them less effective and could eventually render them obsolete, putting millions of lives at risk.
Public Health

Ancora Pharmaceuticals Awarded National Institute Of Health Grant For Continued Malaria Vaccine Research

With exciting pre-clinical results showing that its carbohydrate-based vaccine can combat cerebral malaria (CM), which causes inflammation of the brain, Ancora Pharmaceuticals has received another grant from the National Institute of Health (NIH) to research whether its vaccine candidate will also prevent severe malaria anemia (SMA). The $530,000 Phase I SBIR grant is the third NIH grant Ancora has received. In 2005, the pharmaceutical company was awarded a $3.3 million grant from NIH to develop their current cerebral malaria vaccine candidate. Scientific evidence indicates that severe malarial disease results from the downstream effects of a toxin generated by the malaria parasite. This toxin gives rise to the same clinical manifestations observed in both CM and SMA, leading to the possibility that Ancora"s first vaccine candidate could be successfully used for both. Malaria afflicts up to ten percent of the global population resulting in between two and three million deaths per year. Because of global warming, the World Health Organization (WHO) has predicted that 50 percent of the population will be at risk of this disease by 2010. This latest grant demonstrates NIH"s continued confidence in Ancora"s ability to create cost-effective vaccines utilizing carbohydrate synthesis. The company"s breakthrough method of producing synthetic carbohydrates allows for approaches to bacterial, parasitic, and viral infectious diseases previously unattainable. Ancora Pharmaceuticals is a private venture-backed biopharmaceutical company based in Medford, Massachusetts focused on developing immune system modulation therapeutics using synthetic carbohydrates. Ancora"s automated carbohydrate synthesizer is internationally recognized as the most advanced in the world. Synthetic carbohydrate therapeutics represents an untapped opportunity within the pharmaceutical industry to develop promising vaccines against some of today"s worst infectious diseases. Ancora Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009